New study matches Weight-Loss drugs to bipolar Patients' brain and gut types

NCT ID NCT07213466

First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 27 times

Summary

This study aims to find the best weight-loss medication for people with bipolar disorder by identifying their obesity type—such as 'hungry brain' or 'hungry gut.' About 100 adults aged 18-65 with bipolar or schizoaffective disorder will be assigned one of three FDA-approved drugs (Semaglutide, Naltrexone/Bupropion, or Phentermine/Topiramate) or no medication, plus virtual group therapy. The goal is to see if matching treatment to obesity type is safe and effective for weight loss in this population.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

The condition(s) this trial relates to.

bipolar disorder bipolar I disorder bipolar II disorder Obesity obesity disorder Psychotic Disorders schizoaffective bipolar disorder schizoaffective disorder Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.